Table 2.
Concomitant drugs
| Drugs | Baseline (n = 204) | Week 12 (n = 204) |
|---|---|---|
| Antidiabetic drug | 140 (68.6) | 138 (67.7) |
| Sulfonylurea | 114 (55.9) | 113 (55.4) |
| α-Glucosidase inhibitor | 19 (9.3) | 18 (8.8) |
| Biguanide | 47 (23.0) | 49 (24.0) |
| DPP-4 inhibitor | 8 (3.9) | 7 (3.4) |
| Glinide | 3 (1.5) | 3 (1.5) |
| Thiazolidinedione | 10 (4.9) | 10 (4.9) |
| Other | 1 (0.5) | 0 (0.0) |
| Antihypertensive drug | 121 (59.3) | 123 (60.3) |
| Diuretic drug | 22 (10.8) | 20 (9.8) |
| Calcium channel blocker | 75 (36.8) | 77 (37.8) |
| ACE inhibitor | 9 (4.4) | 8 (3.9) |
| Angiotensin II receptor blocker | 95 (46.6) | 98 (48.0) |
| Direct renin inhibitor | 0 (0.0) | 0 (0.0) |
| α-blocker | 0 (0.0) | 0 (0.0) |
| β-blocker | 17 (8.3) | 18 (8.8) |
| α1β-blocker | 4 (2.0) | 5 (2.5) |
| α2 receptor agonist | 1 (0.5) | 1 (0.5) |
| Other | 2 (1.0) | 2 (1.0) |
| Lipid-lowering agent | 117 (57.4) | 118 (57.8) |
| Statin | 103 (50.5) | 102 (50.0) |
| Fibrate | 12 (5.9) | 12 (5.9) |
| Ezetimibe | 6 (2.9) | 8 (3.9) |
| Probucol | 0 (0.0) | 0 (0.0) |
| EPA | 0 (0.0) | 0 (0.0) |
| Resin | 0 (0.0) | 0 (0.0) |
| Other | 4 (2.0) | 4 (2.0) |
Data are shown as n (%)
DPP-4 dipeptidyl peptidase-4, ACE angiotensin-converting enzyme, EPA eicosapentaenoic acid